News

On October 6, 2015, the Centers for Medicare & Medicaid Services and Office of the National Coordinator for Health Information Technology released Meaningful Use-Stage 2 modifications and Stage 3 final rules.

Judge Rudolph Contreras ruled against the Department of Health and Human Services by saying that pharma companies do not have to offer rural and cancer hospitals that serve low-income populations 340B discounts on orphan drugs.

There is new hope for patients with multiple sclerosis (MS) after positive data on Gilenya and the investigational drug ocrelizumab was presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain.

Soon after the FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC), it approved Opdivo (nivolumab) for an expanded use – to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

On the heels of the Centers for Medicare & Medicaid Services release of the Medicare accountable care organizations (ACO) 2014 quality and financial performance results, tracking the ACO industry for market shifts might be a wise move, according to one industry expert.

The Centers for Medicare & Medicaid Services Office of Minority Health, unveiled the first CMS plan to address health equity in Medicare.There are six key priorities of the CMS Equity Plan for Medicare.

The first biosimilar product was approved this spring. Pharmacists will want to familiarize themselves with this new class of therapies. Below are the five top things that a pharmacist should know about biosimilars.

CMS recently released a proposed draft of its Medicare Reporting Requirements document for 2016 and, for the first time, the guidance includes reporting requirements for Medicare rewards and incentive programs. The new reporting requirement is slated to begin January 1. Are you ready?

Pulmonary fibrosis (PF) organizations and healthcare providers are lauding the update of the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis, which was last updated in 2011.